MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Endocyte Company Profile (NASDAQ:ECYT)

Consensus Ratings for Endocyte (NASDAQ:ECYT) (?)
Ratings Breakdown: 4 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $13.50 (347.02% upside)

Current Analysts' Coverage Summary for Endocyte (NASDAQ:ECYT)
Show:
DateFirmActionRatingPrice TargetActions
1/20/2016Credit SuisseInitiated CoverageOutperform$11.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/4/2015RBC CapitalLower Price TargetOutperform$13.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/8/2015Cantor FitzgeraldReiterated RatingBuy$21.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/3/2015WedbushSet Price TargetBuy$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/30/2014Brean CapitalDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/29/2014Citigroup Inc.Reiterated RatingNeutral$8.00 -> $10.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/25/2014Chardan CapitalReiterated RatingPositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/2/2014Piper JaffrayDowngradeOverweight -> Neutral$13.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/2/2014Robert W. BairdDowngradeOutperform -> Neutral$36.00 -> $8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/24/2014Roth CapitalBoost Price Target$20.00 -> $42.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/25/2014Leerink SwannLower Price Target$21.00 -> $18.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 2/5/2014 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha